The global hemophilia treatment market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Hemophilia is generally caused by gene mutation, and a majority of hemophilia cases are inherited. The market growth is majorly attributed to the increasing cases of hemophilia. The increasing cases of the disease are likely to drive developments in hemophilia treatment in the future years. Further, growing R&D initiatives particularly for the development of therapeutic agents is another major factor anticipated to positively impact market growth. Availability of limited options for the treatment therapy and the growing burden on the regulatory bodies towards its treatment results in increasing R&D efforts. 

In addition, rising awareness campaigns and supportive initiatives plan by the government to commence early screening of neonates, which is expected to boost the demand for diagnostic tools related to hemophilia which in turn will boost the growth of the market. The constantly rising prevalence of bleeding disorders and growing severity with the genetic evolution globally is anticipated to drive overall market growth. As per the World Federation of Hemophilia, hemophilia is more recorded among males and about 1 in 5,000 neonates suffer from type A. This is a rare genetic bleeding disorder projected to have affected around 440,000 people globally in 2018. Agencies like hemophilia Association of America generally offers continuous treatment for patients by introducing different co-pay initiatives.

Some key players operating in the market include Baxter International, Inc., Grifols SA, CSL Ltd., Octapharma AG, Novo Nordisk, among others. These players are aiming to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launches and development in the existing product portfolio, and so on.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Baxter International, Inc., Grifols SA, CSL Ltd., Octapharma AG, Novo Nordisk, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hemophilia Treatment Market by Segment

By Product 

• Plasma Derived Coagulation Factor Concentrate

• Recombinant Coagulation Factor Concentrates

• Desmopressin, Antifibrinolytics

By Type 

• Hemophilia A

• Hemophilia B

Hemophilia C 

Global Hemophilia Treatment Market by Region